Cantargia Q4 2023: Progress with CAN10 and in PDAC - Redeye
Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.
ANNONS
Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.